Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to...
First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says
AzurRx BioPharma has started dosing patients in a Phase 2 clinical trial assessing its investigational therapy MS1819-SD in combination...
New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of...
Prevalence and characterization of chronic rhinosinusitis in patients with non–cystic fibrosis bronc
In this retrospective cohort study, researchers identified the prevalence of chronic rhinosinusitis (CRS) among bronchiectasis patients...
CF patients experience improved lung health with lumacaftor-ivacaftor but with caveats
In adolescent and adult patients with cystic fibrosis taking lumacaftor-ivacaftor (ORKAMBI), the combination drug appears to improve lung...
Can Blood Biomarkers Predict Clinical Response to Azithromycin in Cystic Fibrosis Patients?
Although azithromycin can lower pulmonary exacerbation (PEx) risk in patients with cystic fibrosis (CF), it does not help all patients....